​

Biomea Fusion Stock (NASDAQ:BMEA)

ForecastRevenueOwnershipFinancialsChart
Biomea Fusion by TradingView

Previous Close

$1.52

52W Range

$0.87 - $6.06

50D Avg

$1.41

200D Avg

$1.85

Market Cap

$83.89M

Avg Vol (3M)

$2.07M

Beta

-0.16

Div Yield

-

BMEA Company Profile

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

79

IPO Date

Apr 16, 2021

Website

BMEA Performance

BMEA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-144.07M$-126.14M$-83.63M
Net Income$-138.43M$-117.25M$-80.02M
EBITDA$-144.07M$-124.62M$-82.94M
Basic EPS$-3.83$-3.44$-2.73
Diluted EPS$-3.83$-3.44$-2.73

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
CAMPCAMP4 Therapeutics Corporation
GUTSFractyl Health, Inc. Common Stock
RPTXRepare Therapeutics Inc.
ALXOALX Oncology Holdings Inc.
PMVPPMV Pharmaceuticals, Inc.
STROSutro Biopharma, Inc.
IMUXImmunic, Inc.
CBUSCibus, Inc.
ADVMAdverum Biotechnologies, Inc.
UNCYUnicycive Therapeutics, Inc.